Several proton pump inhibitors are now available over the counter in the United States, with omeprazole (sold as Prilosec OTC) being the first to make the switch back in 2003. Since then, lansoprazole (Prevacid 24HR) and esomeprazole (Nexium 24HR) have joined the OTC lineup, giving millions of Americans direct access to powerful acid-suppressing medications without a prescription. For older adults and their caregivers, this accessibility raises important questions, particularly given the growing body of research examining potential links between long-term PPI use and cognitive health, nutrient absorption, and kidney function. Roughly 10 percent of Americans now use PPIs, making them one of the most commonly prescribed and purchased drug classes in the country.
That prevalence climbs sharply with age, reaching approximately 40 percent among patients aged 70 and older. For families navigating dementia care or working to protect brain health, understanding what these medications do, when they are appropriate, and what the latest research says about their risks is not optional knowledge. It is essential. This article breaks down which PPIs you can buy without a prescription, what they cost, how they should be used according to FDA labeling, and what the 2025 and 2026 research tells us about potential long-term consequences, including nutrient deficiencies that may affect cognitive function.
Table of Contents
- Which Proton Pump Inhibitors Can You Buy Over the Counter Right Now?
- How Much Do Over-the-Counter PPIs Cost, and Are Generics Worth It?
- What the FDA Label Actually Says About How to Use OTC PPIs
- Long-Term PPI Use and Brain Health: What the Research Actually Shows
- Kidney, Bone, and Infection Risks That Caregivers Should Know About
- Newer Alternatives on the Horizon
- What Caregivers and Families Should Do Next
- Conclusion
- Frequently Asked Questions
Which Proton Pump Inhibitors Can You Buy Over the Counter Right Now?
Three PPIs are currently available without a prescription in the United States. Omeprazole (Prilosec OTC) was the first, receiving FDA approval for over-the-counter sale on October 31, 2003, in a 20 mg strength. Lansoprazole (Prevacid 24HR) followed in may 2009 at 15 mg, becoming the first OTC PPI sold in its original prescription formulation. Esomeprazole (Nexium 24HR) came next, approved for OTC sale on March 28, 2014, at a 20 mg dose, which is half the strength of the prescription version. There is also an omeprazole and sodium bicarbonate combination product sold as Zegerid OTC. Not every PPI has made the jump to over-the-counter availability.
Pantoprazole (Protonix), rabeprazole (Aciphex), and dexlansoprazole (Dexilant) all remain prescription-only in the United States. The distinction matters because a doctor or caregiver may reference a specific PPI by name, and assuming all of them can be picked up at a pharmacy without a prescription would be a mistake. If someone on pantoprazole loses prescription coverage, for instance, switching to an OTC alternative is not a one-to-one substitution and should involve a conversation with their physician. It is also worth noting a recent international development. In June 2025, Japan approved its first over-the-counter PPI, a rabeprazole product called Pariet S, manufactured by Eisai. this medication is not available OTC in the United States, but the move signals a broader global trend toward making these drugs more accessible outside the traditional prescription pathway.
How Much Do Over-the-Counter PPIs Cost, and Are Generics Worth It?
One of the practical advantages of the OTC switch is cost. Generic omeprazole can be purchased for as little as $5.34 with a discount coupon, compared to an average retail price of around $22.96. Generic esomeprazole runs under $11 at certain pharmacies when using a discount card. These prices reflect a broader pattern: when patent exclusivity expired for esomeprazole, pantoprazole, and lansoprazole, prices dropped 60 to 80 percent within two years of generic entry. For older adults on fixed incomes, or for families managing the already heavy financial burden of dementia care, those savings are meaningful. However, cheaper does not always mean better in every situation.
The OTC versions of these drugs are dosed lower than their prescription counterparts. Nexium 24HR, for example, contains 20 mg of esomeprazole, while the prescription version delivers 40 mg. Someone who has been managing a serious condition like erosive esophagitis on a prescription-strength PPI should not assume the OTC version will provide equivalent relief. Downgrading without medical guidance can lead to symptom rebound and complications, particularly in older adults who may not communicate discomfort effectively due to cognitive decline. OTC drugs now account for an estimated 48 percent of the PPI market share in the United States. that is a staggering proportion for a drug class that was entirely prescription-based just two decades ago, and it means nearly half of all PPI use in this country happens without direct physician oversight.
What the FDA Label Actually Says About How to Use OTC PPIs
Every OTC PPI currently sold in the United States carries the same basic usage guideline: they are intended for 14-day treatment courses, to be used up to three times per year, for frequent heartburn defined as occurring two or more days per week. PPIs may take one to four days to reach full effectiveness, but each dose provides approximately 24 hours of acid suppression. These are not meant to be taken indefinitely the way a daily vitamin might be. This is where the gap between labeling and reality becomes a problem. Many people start a 14-day course, feel better, and simply keep taking the medication for months or even years.
A 2017-2018 survey found that prescription PPI use among U.S. adults had risen to 8.6 percent, up from 4.1 percent in 1999-2000, and that figure does not fully capture the OTC users who never show up in prescription databases. Among adults aged 70 and older, PPI use reaches roughly 40 percent. For caregivers managing a loved one’s medication regimen, checking whether an OTC PPI has quietly become a permanent fixture in the daily pill organizer is a worthwhile exercise. The practical reality is that many older adults take these medications far beyond the labeled recommendations without ever discussing it with a healthcare provider. In dementia care settings, where the person taking the medication may not be able to articulate symptoms or track their own usage, the risk of indefinite, unsupervised PPI use is especially high.
Long-Term PPI Use and Brain Health: What the Research Actually Shows
The question that matters most to readers of this site is whether long-term PPI use affects the brain. The honest answer is that the evidence is concerning but not conclusive. The strongest established risk connections involve nutrient absorption. Long-term PPI use can reduce the body’s ability to absorb calcium, magnesium, and vitamin B12, all of which play documented roles in neurological function. Vitamin B12 deficiency in particular has been linked to cognitive impairment, memory problems, and symptoms that can mimic or worsen dementia. Beyond nutrient pathways, several observational studies have examined direct associations between PPI use and dementia risk, with mixed results.
Some large population studies have found a modest increased risk, while others have found no significant association after controlling for confounding variables. The critical caveat, emphasized in a review published in Annual Reviews, is that the evidence is almost exclusively observational. Causality has not been definitively established. People who take PPIs long-term tend to be older, sicker, and on more medications, all of which independently raise dementia risk. For caregivers, the practical takeaway is not to panic and immediately stop a PPI, which can cause dangerous acid rebound, but to have a deliberate conversation with a physician about whether continued use is necessary. If a loved one with cognitive decline has been on omeprazole for three years and nobody has revisited the original reason for starting it, that is a conversation worth initiating.
Kidney, Bone, and Infection Risks That Caregivers Should Know About
The potential harms of long-term PPI use extend beyond cognitive concerns. Research published in 2025 and 2026 has further characterized several risks. PPI users face an approximately 1.7 times higher risk of Clostridioides difficile infection, a serious and sometimes fatal gut infection that is already a significant threat in nursing homes and long-term care facilities. Pooled odds ratios across populations range from 1.3 to 2.3, depending on the study. Chronic kidney disease is another area of concern.
Studies have found an independent correlation between PPI use and a 20 to 50 percent increased risk of chronic kidney disease. For older adults who may already have compromised renal function, adding a medication that potentially accelerates kidney decline deserves scrutiny. Hip fractures round out the major risk categories, with pooled risk ratios of 1.20 for short-term use and 1.24 for use lasting three years or longer. In a population where a hip fracture can be a life-altering or even life-ending event, even a modest increase in fracture risk carries real weight. None of these findings should be interpreted as proof that PPIs cause these outcomes. But when a single medication class is associated with increased risks across multiple organ systems, and when that medication is being used by 40 percent of people over 70, the aggregate public health implications are serious enough to warrant careful, individualized decision-making rather than reflexive daily use.
Newer Alternatives on the Horizon
In July 2024, the FDA approved vonoprazan (sold as VOQUEZNA) at a 10 mg dose for heartburn caused by non-erosive gastroesophageal reflux disease. Vonoprazan is not a PPI. It belongs to a newer class called potassium-competitive acid blockers, or PCABs, which suppress acid through a different mechanism and offer a more rapid onset of action.
For now, vonoprazan is prescription-only, but its approval signals that the acid-suppression landscape is evolving. For older adults who have been on PPIs for years without adequate symptom review, the emergence of new drug classes is a reminder that the treatment landscape does not stand still. A medication regimen that made sense five years ago may no longer represent the best available approach, especially if a newer option offers similar benefits with a different risk profile.
What Caregivers and Families Should Do Next
The rising prevalence of OTC PPI use among older adults calls for a more proactive approach from caregivers and families. Prescription PPI use more than doubled between 1999 and 2018, and the OTC market has grown alongside it. If you are managing medications for someone with cognitive decline, add PPIs to the list of drugs you discuss at every medical appointment. Ask whether the original indication still applies, whether the dose is appropriate, and whether a step-down trial, where the dose is gradually reduced under supervision, might be feasible.
Equally important is monitoring for the nutrient deficiencies that long-term PPI use can cause. Requesting periodic blood tests for vitamin B12, magnesium, and calcium levels is a simple step that can catch problems before they compound existing cognitive or physical challenges. Brain health is not built on any single decision. It is the product of hundreds of small, informed choices, and knowing what is in the daily pill organizer is one of them.
Conclusion
Omeprazole, lansoprazole, and esomeprazole are all available over the counter in the United States, making powerful acid suppression accessible without a prescription. For short-term use as directed on the label, these medications are generally considered safe and effective for managing frequent heartburn. The problems emerge when 14-day treatment courses quietly become years-long habits, particularly among older adults who may be most vulnerable to the associated risks of nutrient malabsorption, kidney disease, bone fractures, and gut infections. For those caring for someone with dementia or working to preserve their own cognitive health, the message is not to fear PPIs but to respect them.
They are real medications with real effects on the body, and the fact that they sit on a pharmacy shelf next to antacids does not make them trivial. Talk to a doctor. Review the medication list. Ask the hard questions. That kind of vigilance is one of the most valuable things a caregiver can offer.
Frequently Asked Questions
Can I just stop taking a PPI if I have been on it for a long time?
No. Abruptly stopping a PPI after long-term use can cause rebound acid hypersecretion, where the stomach produces even more acid than before you started the medication. This can cause severe heartburn and discomfort. Work with a doctor to taper the dose gradually over several weeks.
Are OTC PPIs the same strength as prescription versions?
Not always. Nexium 24HR contains 20 mg of esomeprazole, while the prescription version is available at 40 mg. Prevacid 24HR is 15 mg compared to the prescription’s 15 or 30 mg options. If you have been taking a prescription-strength PPI, the OTC version may not provide adequate acid suppression for your condition.
How long does it take for an OTC PPI to start working?
PPIs may take one to four days to reach full effectiveness, though some people notice improvement sooner. They are not designed for immediate relief of acute heartburn symptoms the way antacids are. Each dose provides roughly 24 hours of acid suppression once the medication reaches full effect.
Should I be worried about dementia risk from taking a PPI?
The research is mixed and almost entirely observational, meaning no study has proven that PPIs directly cause dementia. However, long-term PPI use can reduce absorption of vitamin B12, magnesium, and calcium, all of which are important for brain function. If you or a family member uses a PPI regularly, periodic blood work to check these nutrient levels is a reasonable precaution.
My parent with dementia takes omeprazole daily. What should I ask the doctor?
Ask whether the original condition that prompted the PPI is still active, whether the current dose is the lowest effective option, whether a step-down trial is appropriate, and whether any blood tests should be ordered to check for nutrient deficiencies. Also ask whether a different class of medication, such as an H2 blocker, might be sufficient.
Is vonoprazan (VOQUEZNA) better than a PPI?
Vonoprazan works through a different mechanism and has a faster onset of action, but it is prescription-only and relatively new to the U.S. market, having been approved in July 2024. Long-term safety data is more limited compared to PPIs, which have decades of use behind them. Whether it is a better option depends on the individual patient and should be discussed with a gastroenterologist.
